S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Ipsen Biopharmaceuticals, Inc. Announces Key Medical and Commercial Hires (2014/9/10)|
|Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NETs1 in the US with Priority Review|
|Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NET1s in the US with Priority Review and in Europe|
|New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors (2014/7/17)|
|New England Journal of Medicine Publishes Ipsen’s Somatuline® CLARINET® Phase III Results in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors|
|Ipsen: 2014 Half-Year Results and 2014 Objectives (2014/8/29)|
|Ipsen Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014 (2014/8/26)|
|Ipsen Appoints Cynthia Schwalm as President and CEO of Ipsen North America (2014/8/20)|
|Ipsen Presents Preliminary Results of Exploratory Proof-of-Concept Study with Tasquinimod in Four Advanced Tumor Types at the ESMO 2014 Congress (2014/9/27)|
|Susheel Surpal Steps Down as Executive Vice President, Chief Financial Officer of Ipsen to Pursue Other Opportunities (2014/10/2)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
Click above to view more mutual fund data and stats for ipn - Ipsen SA.